Argenx (ARGX) announced its plan to advance the clinical development of ARGX-119, an agonist antibody to muscle-specific kinase, to a registrational study in patients with congenital myasthenic syndromes following the analysis of topline data from the Phase 1b study. Detailed results will be presented at a future medical meeting.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx’s Efgartigimod Study: A Promising Step for ITP Treatment
- Promising Growth Prospects for Argenx Se’s Vyvgart in CIDP and gMG Treatment Drive Buy Rating
- Argenx Gains European Approval for Novel CIDP Treatment
- Argenx price target lowered to EUR 650 from EUR 715 at Morgan Stanley
- Halozyme says Argenx received EU approval for Vyvgart with Enhanze for CIDP